Venenum BioDesign, LLC

Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.

We offer immunological reagents worldwide for diagnostics & research in the following disciplines:

Infectious Diseases (60)
Neuroscience (45)
Inflammation (43)
Veterinary (41)
Cardiac Markers (36)
Gangliosides & Globosides (33)
Tumor Markers (26)
Hormones (22)
Microbial & Plant Toxins (21)
Metabolic Syndrome (15)
Blood Coagulation and Anemia (12)
Biodefense (10)
Kidney Diseases (4)
Fertility and Pregnancy (2)


We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.

Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.

Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.

Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.

Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!

Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.

Alpha Genesis® Inc. (AGI) provides the highest quality nonhuman primate products and bio-research services world-wide, with a customer base that extends across North America, Europe, and Asia. The Alpha Genesis Primate Research Center is a full-service facility that offers Nonhuman Primates for Biomedical Research, Contract Research and Consultation, Primate Housing and CDC Quarantine, and Biological Products and Materials. AGI maintains 100+ acres of primate breeding and holding facilities, and our large inventory of monkeys allows us to best serve your primate research needs. All AGI monkeys are of optimal health and are readily accessible for immediate availability and use. Individual monkey health records available to prospective clients upon request.

Principal research areas currently include: Aging and Metabolic Diseases, Immunogenetics and Immonology, Reproduction, Neurobiology, Physiological Ethology, Psychobiology. Recent research focus: embryonic stem cells, AIDS vaccine research, women's health, developmental disorders, glaucoma and presbyopia, osteoporosis, Parkinson's, movement disorders, diabetes, drug addiction, and obesity.

Veterinary training is available in primate biology, medicine, biomedical research, and behavior. Unique opportunity to work directly with monkeys. Educational opportunities are available to students case-by-case. Interested students should submit a research plan to info@alphagenesisinc.com. Outreach activities are also considered.

Since its inception AGI has grown to serve a broader customer base as we have strengthened our dedication to providing the very best and most cost-effective research and development support to the scientific community. Each AGI employee that works within our AAALAC accredited facilities is highly qualified and carefully trained specifically to complete the job you hired us to do.

If you have questions or would like to place an order, please e-mail AGI at info@alphagenesisinc.com or call toll-free 866.789.MONK (6665). Visit us on the web at www.alphagenesisinc.com or at www.primateresearch.com

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA.
ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital.

- 25 years experience and 2500 customers worldwide
- Premium R&D CRO based in USA with global reach
- Seasoned project managers
- Extensive Academic partnerships
- Flexible business models
- Competitive pricing options
- Industry's largest ever-greening stock compound inventory
- Ongoing investments in novel proprietary chemistry and discovery platforms

One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners.

As the drug development business of Laboratory Corporation of America Holdings (Labcorp) and the world’s most comprehensive drug development #CRO service company, we have helped pharmaceutical and biotech companies develop 100% of the top 50 prescription drugs in the marketplace today.

Because of our broad experience and specialized expertise, we’re in a unique position to supply insights that go above and beyond testing. Together with our clients, we create solutions that transform potential into reality.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.